Relationship Between Chemotherapy Induced Neutropenia And Clinical Efficacy In Advanced Gastric Cancer

Background:The main treatment of advanced gastric cancer is combined chemotherapy. Currently,there has not been a more closely related indicators in clinical application approved by the FDA used to determine the prognosis of advanced gastric cancer.In recent years, many clinical studies have shown that advanced cancer chemotherapy induced neutropenia(CIN) may be associated with clinical efficacy and prognosis, the light or moderate neutropenia may portend a good prognosis and efficacy. Currently, the study of the relationship between CIN and clinical efficacy and prognosis of advanced gastric cancer is very few.AIM:This study aims to investigate the relationship between PFS and the Clinical efficacy of chemotherapy induced neutropenia in patients with advanced gastric cancer receiving first-line FOLFOX6 chemotherapy,so as to provide guidance for clinical judgment advanced gastric cancer.METHODS:Through electronic medical record system to collect Qinghai University Hospital oncology patients with advanced gastric cancer between July 1,2014 – September 31, 2015 treated 120 patients, TNM staging of ⅢC、Ⅳ(AJCC 2010 The Seventh version) and the pathological type adenocarcinoma,there may be an objective e-valuation of the lesion, acceptance FOLFOX6 regimen for at least 4 cycles. Accor- ding to chemotherapy neutropenia extent patients were divided into 4 groups: G0-group(>2.0×109/L),G1 group(1.5×109/L-2.0×109/L),G2 group(1.0×109/L-1.5×109/L), G3 group(<1.0×109/L). Collecting the patient’s sex, age, liver metastasis after 4 cycles of first-line chemotherapy efficacy and PFS(progression-free survival), application SPSS21.0 software for statistical analysis of chemotherapy-induced neutropenia and clinical efficacy and PFS relevance.RESULTS: 1. A total number of 120 patients with advanced gastric cancer by the statistical test showed that chemotherapy induced neutropenia and clinical characteristics including gender, age, presence or absence of liver metastasis was no correlation(P>0.05); 2. Analysis of curative effect showed significant diffence between the four groups in ORR and DCR(P<0.05),the group G1 disease control rate(DCR) the highest(86.7%, P=0.04); 3. By the end of the follow-up date(December31,2015),the m PFS was 156 days. Univariate analysis showed that chemotherapy-induced neutropenia associated w-ith PFS, G1 group patients m PFS compared G0,2,3 group is significantly longer(192 days vs 110 days, P = 0.001; 192 days vs162 days, P = 0.005; 192 days vs132 days, P = 0.001), the difference was statistically significant.CONCLUSION: 1. Advanced gastric cancer patients chemotherapy with moderate CIN may have better clinical efficacy and PFS. 2. Chemotherapy-induced neutropenia and advanced gastric cancer patients clinical characterristics including gender, age, presence or absence of liver metastasis was no correlation.